摘要:
The present invention pertains to the field of pharmaceutical chemistry and discloses 8-(3-aminopropyl)-3-exo-8-azabicyclo[3.2.1]octane-3-amino amide compounds represented by formula I, the pharmaceutical compositions, the preparation method and the use thereof. Such compounds or pharmaceutically acceptable salts thereof can be used as an antagonist of CCR5 in preparing medicaments for treating diseases mediated by CCR5, particularly HIV infection, asthma, rheumatoid arthritis, autoimmune diseases and chronic obstructive pulmonary diseases (COPD).
摘要:
A method is provided for reducing near-field radiation and specific absorption rate (SAR) values in a communications device. The communications device includes a multimode antenna structure transmitting and receiving electromagnetic signals and circuitry for processing signals communicated to and from the antenna structure. The method includes adjusting the relative phase between signals fed to neighboring antenna ports of the antenna structure such that a signal fed to the one antenna port has a different phase than a signal fed to the neighboring antenna port to provide antenna pattern control and to increase gain in a selected direction toward a receive point. The method features using a transmit power lower than the transmit power used in a non-pattern control operation of the antenna structure such that the communications device obtains generally equivalent wireless link performance with the receive point using reduced transmit power compared to the non-pattern control operation, thereby reducing the specific absorption rate.
摘要:
The present disclosure generally relates to highly pure plasmid compositions having low, or undetectable, levels of colanic acid and other contaminants made by a process that comprises purifying plasmid DNA by chromatography, treating the purified plasmid DNA with a polypeptide that digests colanic acid under conditions that digest the colonic acid, and separating the plasmid DNA from the digested colonic acid.
摘要:
The present invention discloses a method for configuring a Physical Downlink Control Channel (PDCCH), a base station and a UE, wherein the base station configures a component carrier or component carriers for monitoring the PDCCH for the UE and notifies the UE about information on the configured component carrier or component carriers so that the UE monitors the PDCCH only over the configured component carrier or component carriers. Stated otherwise, in this way, the UE will operate only over a necessary component carrier or component carriers without monitoring respective component carriers in an LTE-A system to thereby reduce the number of concurrently monitored component carriers, and in the case of nonconsecutive component carriers, also reduce the number of consequently enabled receivers and consequently the amount of consumed power of the UE for monitoring the PDCCH.
摘要:
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
摘要:
The present invention discloses a method and device for judging Radio Link Failure (RLF) in Carrier Aggregation (CA) technology, which are used to effectively judge whether a radio link is failed or not in CA technology. Said method comprises: on an evaluation point, comparing the determined radio link quality parameter of each carrier participating in the RLF judgement with the corresponding radio link quality parameter threshold, determining whether to trigger an in-sync indication or out-of-sync indication on the evaluation point, and judging whether the radio link of the User Equipment (UE) is failed according to the number of the continuously received in-sync indications or out-of-sync indications. The embodiment of the present invention determines whether to trigger an in-sync indication or out-of-sync indication by comparing the radio link quality parameters of the carriers participating in the RLF judgement with the corresponding radio link quality parameter thresholds, and thereby judges that whether the radio link is failed or not in CA technology.
摘要:
The present invention provides a method for notifying a UE of monitored component carriers. The method comprises the following steps: an evolved Node B (eNB) sends an monitoring changing instruction and Component Carriers (CC) corresponding to the instruction to a UE with a Media Access Control (MAC) layer control command; according to the monitoring changing instruction and the corresponding CC, the UE activates or deactivates monitoring of the corresponding CC. The present invention allows the MAC PDU for instructing the UE to increase, decrease or change the monitored CC. Therefore, the configuration can be achieved in a simple and flexible manner and has higher reliability.
摘要:
A system for providing vision contains an aberrometer, a wavefront sensor, and a transfer optical system. The aberrometer is configured to measure a received wavefront. The aberrometer includes a wavefront sensor and a transfer optical system for transferring an input wavefront so as to the provide the received wavefront at or near the wavefront sensor. The system also includes a processor in communication with the aberrometer, a readable memory, and instructions located within the memory. The readable memory contains one or more system error parameters and instructions for calculating the input wavefront based on the received wavefront and the one or more system error parameters.
摘要:
Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted thiadiazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
摘要:
Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.